Physician profile
John Mathews
NPI 1568776391
$6,651.56
in general payments reported to CMS, 2019-2025
19 companies · $655 in 2025
The $655 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,110 · 2020: $70.71 · 2021: $90.67 · 2022: $302 · 2023: $1,392 · 2024: $1,032 · 2025: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,083 · Consulting Fee: $818 · Education: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,083.06 |
| Consulting Fee | $817.50 |
| Education | $177.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $4,515.84 | 2019-2025 | Carvykti, Darzalex, Imbruvica |
| Astellas Pharma US INC | $702.33 | 2019-2025 | Cresemba, Xospata |
| Kite Pharma, INC. | $377.96 | 2023-2025 | Yescarta |
| Abbvie INC. | $197.50 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $135.01 | 2024 | Reblozyl |
| Janssen Biotech, INC. | $127.96 | 2025 | Darzalex, Talvey, Tecvayli |
| Novo Nordisk INC | $125.00 | 2024 | Wegovy |
| Legend Biotech USA INC. | $96.92 | 2024 | |
| Sanofi-Aventis U.S. LLC | $75.13 | 2023 | |
| Daiichi Sankyo INC. | $67.33 | 2024-2025 | Vanflyta |
| Takeda Pharmaceuticals U.S.A., INC. | $57.05 | 2024-2025 | Livtencity |
| Genmab U.S., INC. | $32.19 | 2023-2025 | Epkinly |
| Current Health, INC. | $30.81 | 2023 | |
| Boston Scientific Corporation | $30.52 | 2024 | |
| Geron Corporation | $25.80 | 2025 | Rytelo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iovance Biotherapeutics, INC. | $14.68 | 2025 | Amtagvi |
| Morphosys, US INC. | $14.35 | 2023 | Monjuvi |
| Pharmacyclics LLC, An Abbvie Company | $13.26 | 2023 | Imbruvica |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mathews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.